Comprehensive Hemophilia Treatment Center

Open Clinical Trials

We are committed to advancing hemophilia patient care and facilitating the development of novel treatments through research studies and clinical trials. The development of new strategies, including disease-modifying and curative therapies, form the basis of our progressive approach to hemophilia management for patients at Weill Cornell Medicine.

FIX-LONG Study: A Factor IX (FIX) Gene Transfer, Multi-center Evaluation of the LONG-term Safety and Efficacy Study of SPK-9001 (rAAV-Spark100-hFIX-Padua) in Individuals with Hemophilia B

Diseases:

Blood Disorders | Non-Malignant/Benign Hematology, Hemophilia, Hemophilia B

Location(s):

Upper East Side - Manhattan

Primary Investigator(s):

Catherine McGuinn, MD

A Gene-Transfer, Open-Label, Dose-Escalation Study of SPK-8011 [Recombinant Adeno-Associated Viral Vector with B-Domain Deleted Human Factor VIII Gene] in Individuals with Hemophilia A

Diseases:

Bleeding and Platelet Disorders, Hemophilia, Hemophilia A

Location(s):

Upper East Side - Manhattan

Primary Investigator(s):

Catherine McGuinn, MD

A Longitudinal, Observational Study of Previously Treated Hemophilia Patients (PTPs) Switching Coagulation Replacement Factor Products

Diseases:

Hemophilia

Location(s):

Upper East Side - Manhattan

Primary Investigator(s):

Catherine McGuinn, MD

A Randomized, Multi-Center, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Prophylactic Emicizumab versus No Prophylaxis in Hemophilia A Patients with Inhibitors

Diseases:

Hemophilia A

Location(s):

Upper East Side - Manhattan

Primary Investigator(s):

Catherine McGuinn, MD

Gene therapy, Open-Label, Dose-escalation study of SPK-9001 [adeno-associated viral vector with human factor IX gene] in subjects with hemophilia B

Diseases:

Hemophilia B

Location(s):

Upper East Side - Manhattan

Primary Investigator(s):

Catherine McGuinn, MD

Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) < 6 years with severe hemophilia A (FVIII < 1%)

Diseases:

Hemophilia A

Location(s):

Upper East Side - Manhattan

Primary Investigator(s):

Catherine McGuinn, MD

Clinical Trials Patient Portal Events Contact Us

Weill Cornell Medicine Comprehensive Hemophilia Treatment Center 525 East 68th Street
Payson 695 New York, NY 10065 Phone: (212) 746-3421 Fax: (212) 746-8609